Resurfacing an August move: Marico's Q1 FY26 revenue rose 23%; stake in Plix maker lifted to 60%

In results reported in early August, Marico posted Q1 FY26 consolidated revenue of Rs 3,259 crore, up 23.3% year on year, while net profit rose 8.2% to Rs 513 crore. India revenue grew 27.2% to Rs 2,495 crore, and the company increased its fully diluted stake in Satiya Nutraceuticals, owner of Plix, to 60%.

— Filed Sat, 15 Aug, 2026, 18:03 IST · First seen Sat, 15 Aug, 2026, 18:03 IST · Source Financial Express · BrandWagon

What happened

Marico reported Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by a 27.2% rise in India revenue. It increased its fully diluted stake in Plix

Key facts

  • Q1 FY26 consolidated net profit: Rs 513 crore, up 8.2% YoY
  • Q1 FY26 revenue from operations: Rs 3,259 crore, up 23.31% YoY
  • Total income: Rs 3,315 crore
  • Other income: Rs 56 crore
  • Total expenses: Rs 2,659 crore
  • India revenue: Rs 2,495 crore, up 27.17% YoY
  • International revenue: Rs 764 crore, up 12.91% YoY
  • India profit before tax: Rs 469 crore
  • International profit before tax: Rs 213 crore
  • Marico stake in Satiya Nutraceuticals: 60% on a fully diluted basis

Why this matters

Raising its Plix maker stake to 60% gives Marico control over a fast-growing nutraceutical platform and reinforces wellness as a strategic adjacency.

What to watch

  • Plix revenue growth, repeat purchase rates, offline expansion and contribution to Marico's consolidated sales.
  • Whether India volume growth remains strong after the Q1 growth base and as pricing effects ease.
  • Gross-margin and EBITDA-margin commentary, especially on copra, edible-oil, crude-derivative and packaging-cost movements.
  • Marketing and A&P expense trajectory as Marico funds Plix and other premium categories.
  • Any change in minority ownership, earn-out obligations or further stake purchases in Satiya Nutraceuticals.
  • Competitive launches and discounting from FMCG, nutrition, beauty and digital-first wellness brands.
  • Accelerate Plix distribution from digital-first channels into modern trade, pharmacy, general trade and Marico's wider India network.
  • Launch adjacent wellness, nutrition, beauty-from-within and functional-food products using Plix's consumer base and Marico's R&D capabilities.
  • Increase premiumisation in core India franchises to sustain value growth as volume growth and pricing normalize.
  • Integrate Satiya Nutraceuticals operationally while preserving Plix's founder-led, digital-native brand positioning.
  • Use the higher stake to tighten governance, pursue selective bolt-on wellness acquisitions or consider a path to full ownership if performance remains strong.